Castle Biosciences, Inc.
NASDAQ:CSTLMedical - Diagnostics & Research
+$0.04 today
- Market cap
- $1.03B
- Beta
- 1.02
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.43
Volume 0.38M
Average 0.37M
CSTL Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Castle Biosciences, Inc.NASDAQ: CSTL
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 26.5% from a year ago
Other current liabilities stood at $24.08M at the end of Q1 FY2026, up 26.5% from a year earlier and down 43.1% from the prior quarter. Over 3 fiscal years it compounded at +18.1% a year.
Context
- Other current liabilities amounted to 4.4% of total assets at the end of Q1 FY2026, up 0.6 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +26.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 42.34M USD
- Year-over-year change
- +5369.9%
- 4-year CAGR
- +25.8%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 42.34M | +5369.9% |
| FY2024 | 2024-12-31 | 774K | -97.5% |
| FY2023 | 2023-12-31 | 30.69M | +19.5% |
| FY2022 | 2022-12-31 | 25.67M | +51.9% |
| FY2021 | 2021-12-31 | 16.91M | — |
Other Current Liabilities vs competitors
How CSTL compares with its peers on the latest reported figures
- CSTL's Mar 2026 other current liabilities of $24.08M is the 3rd highest of the 8 companies compared; the peer median is $6.46M.
- Its year-over-year change of +26.5% is the 3rd highest of 8, against a peer median of -24.1%.
- Other current liabilities amounts to 4.4% of total assets for CSTL, versus a peer median of 3.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $90.5M | +79.2% | +14.3% | 13.4% | |
| Jun 2026 | $25.03M | -24.1% | +152.2% | 18.9% | |
| Mar 2026 | $24.08M | +26.5% | +18.1% | 4.4% | |
| Mar 2026 | $11.29M | +48.4% | +10.2% | 3.5% | |
| Mar 2026 | $6.46M | +18.5% | -16.3% | 6.8% | |
| Jun 2026 | $662K | -98.3% | -7.9% | 0.0% | |
| Sep 2026 | $0 | -100.0% | +29.0% | 0.0% | |
| Jun 2026 | $0 | -100.0% | +58.9% | 0.0% | |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding CSTL) | $6.46M | -24.1% | +14.3% | 3.5% | |
Competitors are the stored peer set for CSTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 329.63M | 122.95M | 98.84M | 119.71M | 116.73M |
| Short-term Investments | 0 | 135.68M | 144.26M | 173.42M | 182.78M |
| Net Receivables | 17.28M | 23.48M | 38.3M | 51.22M | 43.38M |
| Inventory | 2.02M | 3.98M | 7.94M | 8.14M | 10.25M |
| Other Current Assets | 4.81M | 6.21M | 6.29M | 7.67M | 7.96M |
| Total Current Assets | 353.74M | 292.29M | 295.64M | 360.15M | 361.1M |
| Property, Plant & Equipment (Net) | 16.88M | 26.5M | 37.74M | 62.71M | 112.24M |
| Goodwill | 0 | 10.69M | 10.69M | 10.69M | 10.69M |
| Intangible Assets | 88.92M | 115.66M | 106.64M | 95.54M | 88.88M |
| Long-term Investments | 1.31M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.72M | 2.2M | 2.63M | 2.15M | 5.65M |
| Total Non-current Assets | 108.83M | 155.04M | 157.71M | 171.08M | 217.46M |
| Total Assets | 462.57M | 447.33M | 453.34M | 531.24M | 578.56M |
| Account Payables | 2.55M | 4.73M | 10.27M | 6.9M | 18.71M |
| Short-term Debt | 0 | 0 | 0 | 278K | 417K |
| Tax Payables | 695K | 37K | 0 | 1.08M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 16.91M | 25.67M | 30.69M | 774K | 42.34M |
| Total Current Liabilities | 24.89M | 36.13M | 47.67M | 49.39M | 68.68M |
| Long-term Debt | 0 | 0 | 0 | 9.75M | 9.64M |
| Deferred Tax Liabilities | 635K | 428K | 206K | 1.61M | 2.34M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 18.29M | 0 | 0 | 0 | 1.5M |
| Total Non-current Liabilities | 25.95M | 12.05M | 14.4M | 26.01M | 39.01M |
| Total Liabilities | 50.83M | 48.18M | 62.07M | 75.4M | 107.68M |
| Common Stock | 25K | 27K | 27K | 28K | 30K |
| Retained Earnings | (93.77M) | (160.91M) | (218.37M) | (200.13M) | (224.28M) |
| Accumulated OCI | 0 | (381K) | 136K | 230K | 267K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 411.74M | 399.15M | 391.27M | 455.84M | 470.87M |
| Total Debt | 8.2M | 13.4M | 15.34M | 26.34M | 36.91M |
| Net Debt | (321.43M) | (109.55M) | (83.51M) | (93.37M) | (79.82M) |
Castle Biosciences, Inc.
NASDAQ:CSTL
Intrinsic Alpha fair value
Locked
Current Price
$33.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.